A Phase 2 Proof-of-Concept Challenge Study Investigating EDP-938 in Respiratory-Syncytial-Virus (RSV) Infected Humans.
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2018
At a glance
- Drugs EDP 938 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Proof of concept; Therapeutic Use
- 12 Feb 2018 New trial record
- 07 Feb 2018 According to an Enanta Pharmaceuticals media release, upon successful completion of the phase I study (NCT03384823), this phase II proof-of-concept challenge study is expected to begin in the fourth quarter of calendar 2018.